Phathom Pharmaceuticals EBITDA vs. Shares Outstanding
| PHAT Stock | USD 8.84 0.13 1.49% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -159 M | Current Value -167 M | Quarterly Volatility 77.2 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.61 | 0.68 |
|
|
For Phathom Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Phathom Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Phathom Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Phathom Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Phathom Pharmaceuticals over time as well as its relative position and ranking within its peers.
Phathom |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Phathom Pharmaceuticals. If investors know Phathom will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Phathom Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.74) | Revenue Per Share 0.44 | Return On Assets (0.58) | Return On Equity (34.89) |
The market value of Phathom Pharmaceuticals is measured differently than its book value, which is the value of Phathom that is recorded on the company's balance sheet. Investors also form their own opinion of Phathom Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Phathom Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Phathom Pharmaceuticals' market value can be influenced by many factors that don't directly affect Phathom Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Phathom Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Phathom Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Phathom Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Phathom Pharmaceuticals Shares Outstanding vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Phathom Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Phathom Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Phathom Pharmaceuticals is rated below average in ebitda category among its peers. It is regarded fifth in shares outstanding category among its peers . At this time, Phathom Pharmaceuticals' EBITDA is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Phathom Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Phathom Shares Outstanding vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Phathom Pharmaceuticals |
| = | (159.05 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Phathom Pharmaceuticals |
| = | 68.38 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Phathom Shares Outstanding Comparison
Phathom Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Phathom Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Phathom Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Phathom Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Phathom Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Phathom Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -34.1 M | -32.4 M | |
| Interest Income | 7.9 M | 8.3 M | |
| Operating Income | -167.3 M | -175.7 M | |
| Net Loss | -201.6 M | -211.7 M | |
| Income Before Tax | -201.6 M | -211.7 M | |
| Total Other Income Expense Net | -34.3 M | -36 M | |
| Net Loss | -178 M | -186.8 M | |
| Net Loss | -201.6 M | -211.7 M | |
| Income Tax Expense | 41.8 M | 43.9 M | |
| Non Operating Income Net Other | -1.8 M | -1.7 M | |
| Change To Netincome | 38.7 M | 47.3 M | |
| Net Loss | (3.93) | (4.13) | |
| Income Quality | 0.68 | 0.53 | |
| Net Income Per E B T | 1.02 | 0.80 |
Phathom Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Phathom Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Phathom Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Phathom Pharmaceuticals' important profitability drivers and their relationship over time.
Use Phathom Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Phathom Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Phathom Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Phathom Pharmaceuticals Pair Trading
Phathom Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Phathom Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Phathom Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Phathom Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Phathom Pharmaceuticals to buy it.
The correlation of Phathom Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Phathom Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Phathom Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Phathom Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Phathom Pharmaceuticals position
In addition to having Phathom Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Theme ETFs Thematic Idea Now
Theme ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Theme ETFs theme has 483 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Theme ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.